THYROLAR-0.25
Clinical safety rating: caution
Comprehensive clinical and safety monograph for THYROLAR-0.25 (THYROLAR-0.25).
Thyroid hormone (liothyronine, L-triiodothyronine or T3) binds to thyroid hormone receptors in the nucleus, altering gene transcription and protein synthesis, leading to increased metabolic rate, oxygen consumption, and thermogenesis.
| Metabolism | Hepatic metabolism primarily via deiodination to reverse T3 (rT3) and further conjugation (glucuronidation, sulfation). Minor metabolism via D1 and D2 deiodinases. |
| Excretion | Renal: ~40% as conjugated metabolites (glucuronides and sulfates); fecal: ~20% via bile; minor biliary elimination of parent drug (<5%). Total renal clearance of iodine: ~30%. |
| Half-life | Levothyroxine (T4): ~7 days; liothyronine (T3): ~1 day. Clinical context: Steady-state achieved in ~5 weeks for T4; T3 half-life shorter leads to more frequent dosing if used alone. |
| Protein binding | >99% bound to thyroxine-binding globulin (TBG), transthyretin, and albumin. T4 binding ~99.97%, T3 binding ~99.7%. |
| Volume of Distribution | T4: 0.15-0.2 L/kg; T3: 0.4-0.6 L/kg. Clinical meaning: T3 distributes more extensively into tissues due to lower protein binding, correlating with its more rapid onset and shorter duration. |
| Bioavailability | Oral: 70-80% for T4 (absorbed primarily in jejunum and ileum); 90-95% for T3. Bioavailability reduced by food, fiber, and certain drugs (e.g., iron, calcium). |
| Onset of Action | Oral (T4): 3-5 days for measurable serum T4 increase; full clinical effect in 2-3 weeks. Oral (T3): 2-4 hours for serum T3 peak; clinical effect within 24-48 hours. IV: Not applicable (no IV formulation). |
| Duration of Action | T4: 1-3 weeks after discontinuation (due to long half-life). T3: 24-72 hours. Clinical note: Once-daily dosing maintains euthyroid state due to T4's long half-life; T3 contribution requires careful monitoring to avoid fluctuation. |
| Molecular Weight | T4: 776.87 Da; T3: 650.98 Da |
Oral, 0.25 mg (1 tablet) once daily; adjust based on TSH response.
| Dosage form | TABLET |
| Renal impairment | No specific dose adjustment required for renal impairment; monitor thyroid function. |
| Liver impairment | No specific dose adjustment for Child-Pugh classes; titrate cautiously due to altered metabolism. |
| Pediatric use | Not recommended for pediatric use; safety and efficacy not established. |
| Geriatric use | Initiate at 0.125 mg orally once daily; titrate slowly based on TSH and cardiac status. |
| 1st trimester | L-thyroxine (T4) and liothyronine (T3) are endogenous hormones; thyroid hormone replacement is essential for maternal and fetal health. Physiological doses are safe and necessary. However, supraphysiologic doses may pose risks of fetal thyrotoxicosis. Monitor thyroid function closely. |
| 2nd trimester | Same as T1: continued replacement therapy is critical; adjust dose as needed based on maternal thyroid function tests. Excessive doses leading to hyperthyroidism should be avoided. |
| 3rd trimester | Same as T2: replacement therapy is safe and necessary. Avoid overtreatment to prevent fetal thyrotoxicosis. |
Clinical note
Comprehensive clinical and safety monograph for THYROLAR-0.25 (THYROLAR-0.25).
| Placental transfer | Thyroid hormones (T4 and T3) cross the placenta to a limited extent; however, T4 is converted to T3 in fetal tissues. Transfer is regulated and generally not harmful at physiological doses. Supraphysiologic doses may lead to excessive fetal exposure. |
| Breastfeeding |
■ FDA Black Box Warning
No boxed warning for THYROLAR-0.25. However, all thyroid hormone preparations should not be used for treatment of obesity or weight loss; large doses may produce serious or life-threatening toxicity.
| Serious Effects |
Untreated hyperthyroidismAcute myocardial infarction (if it leads to thyrotoxicosis)Untreated adrenal insufficiency (may precipitate adrenal crisis)
| Precautions | Cardiovascular effects: potential for tachycardia, palpitations, arrhythmias; caution in patients with coronary artery disease., Endocrine: may mask signs of hyperthyroidism; need to monitor thyroid function tests., Bone: long-term use may reduce bone mineral density., Drug interactions: requires dose adjustment with anticoagulants, diabetes medications, and other drugs that bind to thyroid-binding proteins. |
| Food/Dietary | Avoid high-fiber foods, soy products, walnuts, and cottonseed meal as they may reduce absorption. Simultaneous ingestion of calcium-fortified foods or supplements can interfere. Grapefruit juice may increase T3 levels. Take medication on an empty stomach and maintain consistent dietary habits regarding goitrogenic foods (e.g., cruciferous vegetables, but only in very large amounts). |
Loading safety data…
| Excreted into breast milk in small amounts, but not sufficient to cause adverse effects in the infant. Thyroid hormone replacement during breastfeeding is considered safe and essential for the mother's thyroid status. Monitor infant thyroid function if maternal doses are high. |
| Lactation Rating | L1 (Safest) |
| Teratogenic Risk | Thyroid hormones (T3/T4) do not cross the placenta in significant amounts; exogenous liothyronine/levothyroxine does not increase fetal malformation risk. Placental transfer of maternal TSH and thyroid hormones is regulated in pregnancy. Inadequate maternal thyroid hormone replacement increases risk of fetal neurodevelopmental deficits. No known teratogenicity at therapeutic doses. |
| Fetal Monitoring | Monitor maternal TSH and free T4 every 4-6 weeks during pregnancy, with goal TSH 0.2-2.5 mIU/L in first trimester, 0.3-3.0 mIU/L in second/third. Fetal growth and heart rate monitoring as clinically indicated; consider umbilical cord thyroid function if maternal thyroid disease or treatment is unstable. |
| Fertility Effects | Untreated hypothyroidism is associated with ovulatory dysfunction and infertility; adequate replacement restores fertility. No direct adverse effect of thyroid hormone on fertility. |
| Clinical Pearls | THYROLAR-0.25 contains liothyronine (T3) and liotrix (T4) in a 1:4 ratio. T3 has a rapid onset (hours) and shorter half-life (1-2 days) compared to T4. Monitor serum free T4 and T3 levels, as T4 alone may be misleading. Use with caution in elderly and patients with cardiovascular disease; start at low doses and titrate slowly. May cause rapid shifts in thyroid status; monitor for signs of thyrotoxicosis (tachycardia, weight loss, heat intolerance). |
| Patient Advice | Take exactly as prescribed; do not change dose or stop without consulting your doctor. · Take on an empty stomach, 30-60 minutes before breakfast, with a full glass of water. · Swallow tablet whole; do not crush or chew. · Do not take with foods, multivitamins, or antacids containing calcium or iron; separate by at least 4 hours. · Report symptoms of over-treatment (rapid heartbeat, chest pain, excessive sweating, nervousness) or under-treatment (fatigue, weight gain, cold intolerance, constipation). · Regular blood tests are necessary to monitor thyroid function. · Inform all healthcare providers you are taking this medication. · If you are pregnant, planning to become pregnant, or breastfeeding, discuss with your doctor. |